التفاصيل البيبلوغرافية
| العنوان: |
TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER |
| Document Number: |
20100144795 |
| تاريخ النشر: |
June 10, 2010 |
| Appl. No: |
12/475440 |
| Application Filed: |
May 29, 2009 |
| مستخلص: |
3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder. |
| Inventors: |
Bain, Earle E. (Libertyville, IL, US); Abi-Saab, Walid M. (Dornach, CH); Dutta, Sandeep (Gurnee, IL, US); Garimella, Tushar S. (Skokie, IL, US); Awni, Walid M. (Libertyville, IL, US); Saltarelli, Mario D. (Lake Bluff, IL, US) |
| Assignees: |
ABBOTT LABORATORIES (Abbott Park, IL, US) |
| Claim: |
1. A method of treating attention-deficit/hyperactivity disorder in a subject in need thereof, comprising administering to a human patient in need of treatment for attention-deficit/hyperactivity disorder an amount of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof that is about 2 mg to about 4 mg. |
| Claim: |
2. The method of claim 1, wherein the amount of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof administered is sufficient to provide a plasma area under the curve (AUC) ratio that reduces symptom severity while minimizing adverse drug effect. |
| Claim: |
3. The method of claim 2, wherein mean Cmax is from about 5-15 ng/mL. |
| Claim: |
4. The method of claim 2, wherein the AUC24 for 2 mg QD is about 46 ng.h/mL. |
| Claim: |
5. The method of claim 2, wherein the AUC12 for 4 mg BID ranged from about 72-114 ng.hr/mL. |
| Claim: |
6. The method of claim 1, wherein 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane is administered to the patient in an amount of 4 milligrams administered twice in a twenty-four hour period. |
| Claim: |
7. The method of claim 1, wherein 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane is administered to a patient in an amount of 2 milligrams once in a twenty-four hour period. |
| Claim: |
8. An article of manufacture comprising: (a) a packaging material; (b) a neuronal nicotinic acetylcholine receptor agonist; and (c) a label or package insert contained within the packaging material indicating that 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane is administered in an amount of about 2 mg to about 4 mg. |
| Current U.S. Class: |
514/338 |
| Current International Class: |
61; 61 |
| رقم الانضمام: |
edspap.20100144795 |
| قاعدة البيانات: |
USPTO Patent Applications |
